Single-molecule fluorescence immunoassay kit for detecting GFAP protein of dry plasma spot and preparation method of single-molecule fluorescence immunoassay kit

By optimizing the components of the dried plasma spot eluent and diluent, and combining magnetic bead reagents and specific filter paper, the efficiency and accuracy of GFAP protein detection in dried plasma spot samples were improved, solving the detection problem in areas with poor infrastructure and creating a reliable tool for early screening of Alzheimer's disease.

CN120761624APending Publication Date: 2025-10-10YOUDA BIOTECHNOLOGY (SHANGHAI) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511050688.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-29
Publication Date
2025-10-10

AI Technical Summary

Technical Problem

In existing technologies, GFAP protein detection in dried plasma spot samples suffers from low elution efficiency and large test errors caused by differences in filter paper matrices, which affects detection sensitivity and accuracy, making it difficult to apply to the diagnosis of Alzheimer's disease and other neurological diseases in areas with insufficient infrastructure.

Method used

The formula of the dried plasma spot eluate and diluent components were optimized. A single-molecule fluorescent immunoassay kit for detecting GFAP protein in dried plasma spots was developed using magnetic beads coated with anti-GFAP mouse monoclonal antibody, biotinylated anti-GFAP mouse monoclonal antibody, streptavidin-β-galactosidase reagent, and resorufin β-D-galactoside reagent, combined with specific filter paper.

Benefits of technology

It improves the detection sensitivity and accuracy, breaks through the limitations of traditional liquid samples on cold chain transportation, provides a reliable tool for early screening of Alzheimer's disease, and is suitable for areas with poor infrastructure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120761624A_ABST
    Figure CN120761624A_ABST
Patent Text Reader

Abstract

The invention discloses a single-molecule fluorescence immunoassay kit for detecting dry plasma spot GFAP protein and a preparation method, and belongs to the technical field of immunodetection. The kit provided by the invention comprises an anti-GFAP mouse monoclonal antibody coated magnetic bead reagent, a biotinylated anti-GFAP mouse monoclonal antibody reagent, a streptavidin-beta-galactosidase reagent, a resorufin beta-D-galactoside reagent, a dry plasma spot eluent, a GFAP sample diluent, a GFAP calibration product, a GFAP quality control product and dry plasma spot filter paper. The dry plasma spot eluent contains PEG (Polyethylene Glycol) 6000 with the concentration of 15g / L to 25g / L, NaCl with the concentration of 15g / L to 20g / L, HEPES with the concentration of 11g / L to 12g / L, Triton X-100 with the concentration of 10g / L to 12g / L, EDTA (Ethylene Diamine Tetraacetic Acid) with the concentration of 4.5 mmol / L to 5.5 mmol / L, EGTA (Ethylene Glycol Terephthalate) with the concentration of 1.5 g / L to 2.0 g / L and BSA (Bovine Serum Albumin) with the concentration of 1.2 g / L to 1.8 g / L, and the pH value is adjusted to 7.3 to 7.5 by NaOH; aiming at the bottleneck problem of trace GFAP protein detection in a dried plasma spot sample, the detection sensitivity, accuracy and filter paper applicability are improved by optimizing an eluent formula, diluent components and a detection system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of immune detection, and relates to a single-molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots and a preparation method thereof. Background Art

[0002] Glial fibrillary acidic protein (GFAP), a key inflammatory / immune (I) biomarker, is increasingly gaining clinical application value in Alzheimer's disease (AD) and other neurological disorders. GFAP is a 55 kDa intermediate filament protein expressed almost exclusively in astrocytes, forming a core component of their cytoskeleton. In response to inflammation, injury, or pathological stimulation of the central nervous system, astrocytes become activated and express GFAP in high amounts. In AD, elevated plasma GFAP levels are significantly associated with early Aβ pathology in the brain, such as amyloid positivity (PET), and may even precede elevated p-Tau levels. Furthermore, higher GFAP levels predict a higher risk of future progression to AD dementia. Therefore, GFAP testing can serve as a powerful tool for identifying individuals in the early stages of AD pathology, offering significant value in risk screening, prognosis, and auxiliary diagnosis.

[0003] Existing technologies (e.g., Chinese patent applications CN112485445A and CN117074701A) require blood samples (whole blood, serum, plasma) used to measure GFAP to adhere to strict time-limited and temperature-dependent handling, transportation, and storage regulations. This restricts the use of these samples in environments lacking appropriate infrastructure, such as rural areas where laboratory infrastructure is relatively scarce.

[0004] Dried plasma spot venous blood samples maintain biomarker stability at room temperature, making them suitable for areas with limited infrastructure. This technology has been successfully applied in neonatal metabolic disease screening and HIV testing, but its application in the diagnosis of AD and other neurological diseases is still in the research stage. This is because biomarkers such as GFAP have extremely low concentrations in the early stages of AD, such as plasma GFAP <10 pg / mL. The filter paper matrix of dried plasma spot samples causes some protein adsorption loss, significantly reducing elution efficiency, which in turn affects detection sensitivity and batch-to-batch reproducibility.

[0005] How to improve the elution efficiency of dried plasma spot samples, avoid test errors caused by differences in filter paper matrices, and improve test accuracy have become technical problems that need to be urgently solved in applying dried plasma spot sample technology to the diagnosis of AD and other neurological diseases. Summary of the Invention

[0006] The purpose of the present invention is to provide a single-molecule fluorescent immunoassay kit and preparation method for detecting GFAP protein in dried plasma spots, thereby improving the elution efficiency of dried plasma spot samples, reducing test errors caused by differences in filter paper matrices, and improving test accuracy, thereby breaking through the technical bottleneck of the application of dried plasma spot sample technology in the diagnosis of AD and other neurological diseases.

[0007] The technical solution adopted by the present invention provides a single-molecule fluorescent immunoassay kit for detecting GFAP protein in dried plasma spots. The key point is that the kit includes an anti-GFAP mouse monoclonal antibody-coated magnetic bead reagent, a biotinylated anti-GFAP mouse monoclonal antibody reagent, a streptavidin-β-galactosidase reagent, a resorufin β-D-galactoside reagent, a dried plasma spot eluate, a GFAP sample diluent, a GFAP calibrator, a GFAP quality control product and dried plasma spot filter paper; the dried plasma spot eluate contains 15g / L to 25g / L PEG 6000, 15g / L to 20g / L NaCl, 11g / L to 12g / L HEPES, and 10g / L to 12g / L Triton. X-100, 4.5mmol / L~5.5mmol / L EDTA, 1.5g / L~2.0g / L EGTA and 1.2g / L~1.8g / L BSA, the matrix is ​​water, and the pH value is adjusted to 7.3~7.5 with NaOH; streptavidin-β-galactosidase reagent is abbreviated as SBG reagent, and resorufin β-D-galactoside reagent is abbreviated as RGP reagent.

[0008] Furthermore, the dried plasma spot eluate further comprises 15 g / L to 20 g / L of hydroxypropyl-β-cyclodextrin, 5 g / L to 10 g / L of trehalose, and 1.0 g / L to 2.0 g / L of cocamidopropyl betaine.

[0009] Furthermore, the dried plasma spot eluate further includes 0.2 g / L to 0.6 g / L of a preservative, and the preservative is Proclin 300 or sodium azide.

[0010] Specifically, the GFAP calibrator contains 8 concentration points: 1000 pg / mL, 333.3 pg / mL, 111.1 pg / mL, 37.04 pg / mL, 12.35 pg / mL, 4.12 pg / mL, 1.37 pg / mL and 0 pg / mL; the working concentration range of the magnetic bead reagent coated with anti-GFAP mouse monoclonal antibody is 0.8×10 7 beads / mL~1.2×10 7beads / mL; the working concentration range of the biotinylated anti-GFAP mouse monoclonal antibody reagent is 0.3 μg / mL to 0.5 μg / mL; the working concentration range of the SBG reagent is 80 pM to 120 pM; the working concentration range of the RGP reagent is 35 μg / mL to 40 μg / mL; the dried plasma spot filter paper includes any one of Whatman 903 filter paper, Hahnemühle 2992 filter paper, PerkinElmer 226 filter paper, or Ahlstrom 226 filter paper.

[0011] Specifically, the GFAP sample diluent contains: 18 g / L to 22 g / L BSA, 7.5 g / L to 8.5 g / L chloride, 0.9 g / L to 1.2 g / L KH2PO4, 10 g / L to 12 g / L Na2HPO4·7H2O, 9.5 mmol / L to 10.0 mmol / L EDTA, 1.8 g / L to 2.2 g / L surfactant, and 9.5 mg / L to 10.5 mg / L blocking agent. The matrix is ​​water, and the pH is adjusted to 7.3 to 7.5 with NaOH.

[0012] Preferably, the chloride salt is KCl and NaCl in a mass ratio of 1:38-40; the surfactant is Surfactant 10G; and the blocker is TRU Block blocker.

[0013] The present invention relates to a method for preparing a single-molecule fluorescent immunoassay kit for detecting GFAP protein in dried plasma spots. The method is used to prepare the single-molecule fluorescent immunoassay kit for detecting GFAP protein in dried plasma spots. The key to the preparation method is that the method comprises: S1, preparing a magnetic bead reagent by coating magnetic beads with anti-GFAP mouse monoclonal antibody, S2, preparing a biotinylated anti-GFAP mouse monoclonal antibody reagent, S3, preparing an SBG reagent, S4, preparing an RGP reagent, S5, preparing a dried plasma spot eluate, S6, preparing a GFAP sample diluent, S7, preparing a GFAP calibrator, and S8, preparing a GFAP quality control product.

[0014] Specifically, step S1 includes S1-1, replacement of the buffer by coating the anti-GFAP mouse monoclonal antibody, S1-2, preparation of coated magnetic beads, S1-3, preparation of the magnetic bead buffer, and S1-4, preparation of the magnetic bead reagent product coated with the anti-GFAP mouse monoclonal antibody;

[0015] Step S1-1 is to concentrate and replace the solution through an ultrafiltration tube. Specifically, the coated anti-GFAP mouse monoclonal antibody solution is added to the ultrafiltration tube, centrifuged at 13,000×g to 15,000×g for 4 to 6 minutes, and then the solution is repeatedly added with MES buffer for 3 to 4 times to collect the antibody. The concentration of the coated anti-GFAP mouse monoclonal antibody after the solution replacement is measured using an ultramicro UV spectrophotometer and recorded as the coated antibody concentration value;

[0016] Step S1-2 is to wash the magnetic beads with 0.01M sodium hydroxide, purified water, and MES buffer in sequence, activate the magnetic beads with EDC and NHS at room temperature, add the coated anti-GFAP mouse monoclonal antibody after the replacement solution, and coat the magnetic beads at room temperature for 1.5 hours to 2 hours, and add BSA to block the magnetic beads to obtain coated magnetic beads;

[0017] In step S1-3, a magnetic bead storage buffer solution is prepared. The prepared magnetic bead storage solution contains 8 g / L to 12 g / L BSA, 5 g / L to 6 g / L Tris HCl, 1.3 g / L to 2.0 g / L Tris Base, 2.5 g / L to 3.0 g / L NaCl, 0.5 g / L to 1.5 g / L Tween 20, 9.5 mmol / L to 10.0 mmol / L EDTA, and 0.3 g / L to 0.8 g / L preservative. The matrix is ​​water, and the pH value is adjusted to 7.7 to 7.9 with NaOH.

[0018] Step S1-4 is to calculate the required volume of magnetic bead buffer and the volume of anti-GFAP mouse monoclonal antibody-coated magnetic beads based on the anti-GFAP mouse monoclonal antibody concentration measured in step S1-1, so that the working concentration range of the obtained anti-GFAP mouse monoclonal antibody-coated magnetic bead reagent is 0.8×10 7 beads / mL~1.2×10 7 beads / mL.

[0019] Furthermore, step S2 includes S2-1, replacement buffer of anti-GFAP mouse monoclonal antibody labeled with biotin, S2-2, labeling anti-GFAP mouse monoclonal antibody with biotin, S2-3, preparation of biotinylated antibody buffer, and S2-4, preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent product.

[0020] Step S2-1 involves concentrating and replacing the solution using an ultrafiltration tube. Specifically, a biotin-labeled anti-GFAP mouse monoclonal antibody solution is added to an ultrafiltration tube, concentrated by centrifugation at 13,000 × g to 15,000 × g for 4 to 6 minutes, and the solution is repeatedly added with PBS buffer for 3 to 4 times to collect the antibody. The concentration of the biotin-labeled anti-GFAP mouse monoclonal antibody after the replacement solution is determined using an ultramicro-UV spectrophotometer.

[0021] Step S2-2 comprises dissolving NHS-PEG4-Biotin in dimethyl sulfoxide to prepare a biotin concentrate, which is then diluted with PBS buffer to a 10 mM biotin working solution; adding the 10 mM biotin working solution to the replaced biotin-labeled anti-GFAP mouse monoclonal antibody solution for labeling, vortex mixing, and reacting at room temperature in the dark for 50 to 70 minutes to obtain a crude biotinylated antibody product, wherein the molar ratio of the biotin-labeled anti-GFAP mouse monoclonal antibody to biotin is 1:10; purifying the product by ultrafiltration to remove free biotin to obtain a purified biotinylated antibody, and measuring the concentration of the purified biotinylated antibody by an ultramicro-UV spectrophotometer;

[0022] In step S2-3, a biotinylation antibody buffer is prepared, which comprises 18 g / L to 22 g / L BSA, 7.5 g / L to 8.5 g / L chloride, 0.9 g / L to 1.2 g / L KH2PO4, 10 g / L to 12 g / L Na2HPO4·7H2O, 4.5 mmol / L to 5.5 mmol / L EDTA, 0.5 g / L to 1.5 g / L Tween20, and 0.3 g / L to 0.8 g / L preservative. The matrix is ​​water, and the pH is adjusted to 7.3 to 7.5 with NaOH. The chloride is KCl and NaCl at a mass ratio of 1:38 to 40.

[0023] Step S2-4 is to calculate the required volume of biotinylated antibody buffer and the volume of purified biotinylated antibody based on the concentration of the purified biotinylated antibody measured in step S2-2, so that the working concentration range of the obtained biotinylated anti-GFAP mouse monoclonal antibody reagent is 0.3 μg / mL to 0.5 μg / mL.

[0024] Furthermore, the above-mentioned step S3 is to dilute the streptavidin-β-galactosidase concentrate to a working concentration range of 80pM to 120pM using SBG diluent, wherein the SBG diluent contains 25g / L to 35g / L BSA, 8g / L to 12g / L sucrose, 7.5g / L to 8.5g / L chloride salt, 0.9g / L to 1.2g / L KH2PO4, 10g / L to 12g / L Na2HPO4·7H2O, 0.5g / L to 1.5g / L Tween 20, 0.05g / L to 0.15g / L MgCl2, and 0.3g / L to 0.8g / L preservative. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH; the above-mentioned chloride salt is KCl and NaCl with a mass ratio of 1:38 to 40.

[0025] Furthermore, the above-mentioned S4 step is to dissolve resorufin-β-D-galactoside in dimethyl sulfoxide, and then dilute it with RGP diluent to a working concentration range of 35 μg / mL to 40 μg / mL, wherein the above-mentioned RGP diluent contains 8.0 g / L to 9.0 g / L of chloride salt, 0.15 g / L to 0.30 g / L of KH2PO4, 2.0 g / L to 2.5 g / L of Na2HPO4·7H2O, 0.005 g / L to 0.015 g / L of poloxamer, and 0.3 g / L to 0.8 g / L of preservative. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH; the above-mentioned chloride salt is KCl and NaCl with a mass ratio of 1:39 to 42.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] This invention addresses the bottleneck issue of detecting trace amounts of GFAP protein in dried plasma spot samples. By optimizing the eluent formulation, diluent components, and detection system, the assay improves sensitivity, accuracy, and filter paper compatibility. Experimental data from this invention demonstrate that the optimized kit meets clinical requirements for low-concentration GFAP detection, matrix interference resistance, and room-temperature stability. This overcomes the limitations of traditional liquid samples in cold chain transportation and point-of-care testing, providing a reliable tool for early screening of Alzheimer's disease (AD). BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 is a linear graph of sample 1-1 of the kit of the present invention;

[0029] Figure 2 is a linear graph of sample 4-1 of the kit of the present invention;

[0030] Figure 3 is a linear graph of sample 4-2 of the kit of the present invention;

[0031] Figure 4 is a linear graph of sample 4-3 of the kit of the present invention;

[0032] Figure 5 It is a linear graph of sample 4-4 of the kit of the present invention. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described herein are intended only to describe particular embodiments and are not intended to limit the present invention. In addition, for numerical ranges herein, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. The intermediate value within any stated value or stated range, and each smaller range between any other stated value or intermediate value within the stated range, is also encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be illustrative only.

[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0038] If the specific conditions are not specified in the examples, the experiments can be carried out under conventional conditions; if the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially. All reagents and materials used in the present invention were purchased by Quanxin Quanyi (Shanghai) Life Science Technology Co., Ltd., including:

[0039] TRU Block blockers were obtained from Meridian Life Science's TRU Block TM The ULTRA product is an active immune blocker that uses a combination of recombinant immunoglobulin and specific binders to precisely eliminate interference through an active steric hindrance mechanism.

[0040] Whatman 903 filter paper was from GE Healthcare;

[0041] Hahnemühle 2992 filter paper was from Hahnemühle FineArt GmbH;

[0042] PerkinElmer 226 filter paper was from PerkinElmer;

[0043] Ahlstrom 226 filter paper comes from Oyj Company.

[0044] Example 1

[0045] In this example, a single-molecule fluorescence immunoassay kit for detecting GFAP protein in stem plasma plaques was prepared. The kit of this example includes a working concentration range of 1.0×10 7 The specific preparation steps are as follows: beads / mL anti-GFAP mouse monoclonal antibody-coated magnetic beads, biotinylated anti-GFAP mouse monoclonal antibody with a working concentration range of 0.4 μg / mL, SBG reagent with a working concentration range of 100 pM, RGP reagent with a working concentration range of 37.5 μg / mL, dried plasma spot eluent, GFAP sample diluent, GFAP calibrator, GFAP quality control, and dried plasma spot filter paper.

[0046] S1. Prepare magnetic bead reagent by coating magnetic beads with anti-GFAP mouse monoclonal antibody:

[0047] S1-1, coating anti-GFAP mouse monoclonal antibody replacement buffer:

[0048] Add 50 mM MES buffer to the ultrafiltration tube, let it stand for 10 min, and centrifuge it at 14,000 × g for 5 min at 20°C.

[0049] Transfer the coated anti-GFAP mouse monoclonal antibody to an ultrafiltration tube, add 50 mM MES buffer, and perform ultrafiltration using a centrifuge. Concentrate by centrifugation at 14,000 × g for 5 min at 20°C, and repeat the cycle of adding MES buffer three times.

[0050] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1000 × g, 2 min, 20 ° C;

[0051] Rinse the ultrafiltration tube with 50 mM MES and then load it into a centrifuge tube. Centrifuge at 1000 × g for 2 min at 20°C.

[0052] The obtained antibodies were collected and the concentration of the anti-GFAP mouse monoclonal antibody (coating) after the liquid was changed was determined by ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (coating) concentration value, recorded as the coating antibody concentration value.

[0053] S1-2. Preparation of coated magnetic beads:

[0054] The magnetic beads were washed three times with 0.01 M sodium hydroxide, twice with purified water, and once with MES buffer. The beads were activated with EDC and NHS at room temperature for 30 min. Anti-GFAP mouse monoclonal antibody was added and coated at room temperature for 2 h.

[0055] The beads were blocked with 1% BSA solution at room temperature for 45 minutes, and the magnetic beads were washed with magnetic bead buffer and stored to obtain coated magnetic beads.

[0056] S1-3. Preparation of magnetic bead buffer:

[0057] Weigh 750 g of purified water, 5.5 g of Tris HCl, 1.6 g of Tris Base, and 2.8 g of NaCl on a balance and add them to a 2 L beaker. Use a pipette to draw 0.5 g of Proclin 300, 1.0 g of Tween 20, and 19.2 mL of 0.5 M EDTA solution in sequence. Place the beaker on a magnetic stirrer and stir at 500 rpm for 20 min.

[0058] Stop stirring, weigh 10 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0059] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.81 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 500 rpm for 10 minutes, and the mixture was filtered through 0.22 μm.

[0060] S1-4. Preparation of magnetic beads reagent coated with anti-GFAP mouse monoclonal antibody:

[0061] Based on the anti-GFAP mouse monoclonal antibody concentration measured in step S1-1, calculate the required volume of magnetic bead buffer and the volume of anti-GFAP mouse monoclonal antibody-coated magnetic beads. Add the magnetic bead buffer to the EP tube, add the coated magnetic beads to the EP tube, and mix on a roller mixer at 60 rpm for 20 min.

[0062] The working concentration range of the obtained anti-GFAP mouse monoclonal antibody coated magnetic beads reagent is 1.0×10 7 beads / mL, recorded as magnetic bead reagent sample 1.

[0063] S2. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent

[0064] S2-1. Replacement buffer for biotin-labeled anti-GFAP mouse monoclonal antibody:

[0065] PBS buffer was added to the ultrafiltration tube, allowed to stand for 10 min, and centrifuged at 14,000 × g for 5 min at 20°C.

[0066] Transfer the biotin-labeled anti-GFAP mouse monoclonal antibody to an ultrafiltration tube, add PBS buffer, and use a centrifuge for ultrafiltration. Centrifuge at 14,000 × g for 5 min and concentrate at 20°C. Repeat the cycle of adding PBS buffer for 3 times.

[0067] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1000 × g, 2 min, 20 ° C;

[0068] The ultrafiltration tube was rinsed (PBS buffer was added to the inner tube) and then loaded into a centrifuge tube. The centrifugation conditions were 1000 × g, 2 min, 20 °C.

[0069] The obtained antibodies were collected and the concentration of the biotin-labeled anti-GFAP mouse monoclonal antibody after the liquid exchange was determined using an ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (biotinylated) concentration value. The antibody concentration was diluted to 1 mg / mL using PBS buffer.

[0070] S2-2, anti-GFAP mouse monoclonal antibody labeled with biotin:

[0071] After removing the 2 mg / tube of EZ-Link NHS-PEG4-Biotin from a -20°C environment, equilibrate at room temperature for 30 minutes. Pipette 100 μL of dimethyl sulfoxide and add it to the biotin tube. Place the EP tube on a vortexer and mix for 30 seconds to obtain a biotin concentrate.

[0072] Add PBS buffer to the EP tube, pipette the biotin concentrate to prepare a 10 mM biotin dilution, and mix on a vortex for 10 seconds;

[0073] Add 5.3 μL of 10 mM biotin diluent to the EP tube containing 200 μg of antibody, mix on a vortex for 30 seconds, and place the centrifuge tube containing the reaction solution in a dark place at room temperature for 60 minutes;

[0074] Add PBS buffer to the ultrafiltration tube, let it stand for 10 minutes, centrifuge it, concentrate it at 14,000 × g for 5 minutes, and ultrafilter it at 20°C. Repeat this operation three times.

[0075] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1000 × g, 2 min, 20 ° C;

[0076] The ultrafiltration tube was then rinsed with PBS buffer and then loaded into a centrifuge tube. The centrifugation conditions were 1000 × g, 2 min, 20°C to collect the biotinylated antibody.

[0077] The concentration of the purified biotinylated antibody was determined using an ultra-micro-volume UV spectrophotometer.

[0078] S2-3. Preparation of biotinylated antibody buffer:

[0079] Weigh 900 g of purified water, 1.1 g of KH2PO4, 11.1 g of Na2HPO4·7H2O, 0.20 g of KCl, and 7.80 g of NaCl (the mass ratio of KCl to NaCl is 1:39) into a 2 L beaker.

[0080] 10 mL of 0.5 M EDTA solution, 1.0 g of Tween 20, and 0.5 g of Proclin 300 were pipetted into the beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 500 rpm for 15 min.

[0081] Stop stirring, weigh 19.5 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0082] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 500 rpm for 10 minutes, and the mixture was filtered through 0.22 μm.

[0083] S2-4. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent:

[0084] Based on the concentration of the purified biotinylated antibody measured in step S2-2, calculate the required volume of biotinylated antibody buffer and the volume of the purified biotinylated antibody. Add the required biotinylated antibody buffer to the EP tube, add the required biotinylated antibody to the EP tube, and place the tube on a roller mixer at 60 rpm to mix for 20 minutes. The resulting biotinylated anti-GFAP mouse monoclonal antibody reagent has a working concentration range of 0.4 μg / mL. This is recorded as biotinylated antibody reagent sample 1.

[0085] S3. Preparation of SBG reagent:

[0086] Weigh 750 g of purified water, 1.1 g / L KH2PO4, 7.80 g of NaCl, 0.20 g of KCl (the mass ratio of KCl to NaCl is 1:39), 11.3 g of Na2HPO4·7H2O, and 10.0 g of sucrose on a balance and add them to a 2 L beaker in sequence;

[0087] Pipette 0.994 mL of 1 M MgCl2 solution (corresponding to 0.095 g of MgCl2), weigh 1.0 g of Tween20 and 0.5 g of Proclin300, and add them to a 2 L beaker in sequence. Place the beaker on a magnetic stirrer and stir at 500 rpm for 30 min.

[0088] Stop stirring, weigh 30.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0089] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 500 rpm for 30 minutes, and the mixture was filtered through a 0.22 μm filter membrane to obtain a SBG dilution solution;

[0090] Calculate the required volume based on the target working concentration of the SBG reagent and the labeled concentration of the streptavidin-β-galactosidase concentrate. Use a graduated cylinder and pipette to measure the required volume of SBG diluent and add it to a 200-mL beaker. Use a pipette to draw up the required volume of streptavidin-β-galactosidase concentrate and add it to the beaker. Place the beaker on a magnetic stirrer and stir at 500 rpm for 20 minutes to obtain an SBG reagent with a working concentration range of 100 pM, which is recorded as SBG reagent sample 1.

[0091] S4. Preparation of RGP reagent:

[0092] 950 g of purified water, 0.20 g of KH2PO4, 0.21 g of KCl, 8.29 g of NaCl (the mass ratio of KCl to NaCl is 1:40), 2.3 g of Na2HPO4·7H2O, 0.5 g of Proclin300, and 0.010 g of poloxamer were weighed on a balance and added to a 2 L beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 500 rpm for 60 min. The pH value was adjusted to 7.40 using 1 M NaOH solution. The volume was made up to 1000 g with purified water and stirred at 500 rpm for 15 min. The mixture was filtered through 0.22 μm to obtain an RGP dilution.

[0093] A pharmaceutical bottle containing resorufin-β-D-galactoside solid, referred to as an RGP pharmaceutical bottle, was taken out from a -20°C environment and equilibrated at room temperature for 60 minutes. 1 mL of dimethyl sulfoxide (DMSO) was pipetted and then added to the equilibrated RGP pharmaceutical bottle. The RGP pharmaceutical bottle was placed on a vortex mixer for 10 seconds and then mixed on a roller mixer at 60 rpm for 30 minutes until the solid in the bottle was completely dissolved, thereby obtaining an RGP / DMSO solution.

[0094] Calculate the required volume based on the target working concentration of the RGP reagent and the content labeled on the RGP drug bottle; use a graduated cylinder and pipette to measure the required volume of RGP diluent and add it to a 1L brown glass bottle; use a pipette to draw up the required volume of RGP / DMSO solution and add it to the glass bottle. Place the glass bottle on a magnetic stirrer and stir at 500 rpm for 250 minutes to obtain an RGP reagent with a working concentration range of 37.5 μg / mL, which is recorded as RGP reagent sample 1.

[0095] S5. Preparation of dried plasma spot eluate:

[0096] Weigh 800 g of purified water, 11.7 g of HEPES, 17.5 g of NaCl, 1.8 g of EGTA, and 19.6 g of PEG6000 on a balance and add them sequentially to a 2 L beaker. Use a pipette to draw up 10.0 mL of 0.5 M EDTA solution and 6 mL of 5 M NaOH solution, weigh 11.0 g of Triton X-100 and 0.5 g of Proclin 300, and add them sequentially to the beaker. Place the beaker on a magnetic stirrer and stir at 500 rpm for 30 min.

[0097] Stop stirring, weigh 1.5 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0098] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 500 rpm for 20 minutes. The mixture was filtered with a 0.22 μm filter membrane to obtain a dry plasma spot eluate, which was recorded as eluate sample 1.

[0099] S6, GFAP sample diluent:

[0100] Weigh 650 g of purified water, 1.1 g of KH2PO4, 11.0 g of Na2HPO4·7H2O, 0.20 g of KCl, and 7.80 g of NaCl (the mass ratio of KCl to NaCl is 1:39) on a balance and add them sequentially to a 2 L beaker. Pipette 19.5 mL of 0.5 M EDTA solution, weigh 0.5 g of Proclin 300, 1.9 g of surfactant Surfactant 10G, and 10.0 mg of blocking agent TRUBlock, and add them sequentially to the beaker. Place the beaker on a magnetic stirrer and stir at 500 rpm for 30 min.

[0101] Stop stirring, weigh 19.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0102] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 500 rpm for 20 minutes. The mixture was filtered through a 0.22 μm filter membrane to obtain a GFAP sample dilution solution, which was recorded as dilution sample 1.

[0103] S7. Preparation of GFAP Calibrators:

[0104] According to the results of GFAP recombinant antigen traceability, GFAP calibrator diluent was used to dilute the samples to the target concentrations of 1000 pg / mL, 333.3 pg / mL, 111.1 pg / mL, 37.04 pg / mL, 12.35 pg / mL, 4.12 pg / mL, 1.37 pg / mL and 0 pg / mL, which were recorded as calibrator samples.

[0105] S8. Preparation of GFAP quality control product:

[0106] According to the results of GFAP recombinant antigen traceability, the GFAP calibrator was diluted to the target concentration with GFAP calibrator diluent, and then the quality control product was assigned a value using the assignment program. The assignment range was target value ± 3SD, and it was recorded as the quality control sample.

[0107] S9. Kit Assembly:

[0108] The magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, eluent sample 1, diluent sample 1, calibrator sample and quality control sample prepared above were respectively combined with different filter papers to obtain different kit samples. The specific kit sample numbers and filter papers used are shown in Table 1.

[0109] Table 1: Reagents and filter paper combinations for different kits

[0110]

[0111] Example 2

[0112] In this example, a single-molecule fluorescence immunoassay kit for detecting GFAP protein in stem plasma plaques was prepared. The kit of this example includes a working concentration range of 1.2×10 7 The specific preparation steps are as follows: beads / mL anti-GFAP mouse monoclonal antibody-coated magnetic beads, biotinylated anti-GFAP mouse monoclonal antibody with a working concentration range of 0.3 μg / mL, SBG reagent with a working concentration range of 80 pM, RGP reagent with a working concentration range of 40 μg / mL, dried plasma spot eluent, GFAP sample diluent, GFAP calibrator, GFAP quality control product, and dried plasma spot filter paper.

[0113] S1. Prepare magnetic bead reagent by coating magnetic beads with anti-GFAP mouse monoclonal antibody:

[0114] S1-1, coating anti-GFAP mouse monoclonal antibody replacement buffer:

[0115] Add 50 mM MES buffer to the ultrafiltration tube, let it stand for 12 min, and centrifuge it at 13,000 × g, 6 min, and 18°C.

[0116] The coated anti-GFAP mouse monoclonal antibody was transferred to an ultrafiltration tube, 50 mM MES buffer was added, and ultrafiltration was performed using a centrifuge. The tube was concentrated by centrifugation at 13,000 × g for 6 min at 18°C, and the MES buffer was added four times.

[0117] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1200 × g, 1 min, and 18 °C.

[0118] The ultrafiltration tube was then rinsed with 50 mM MES and loaded into a centrifuge tube. The centrifugation conditions were 1200 × g, 1 min, and 18°C.

[0119] The obtained antibodies were collected and the concentration of the anti-GFAP mouse monoclonal antibody (coating) after the liquid was changed was determined by ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (coating) concentration value, recorded as the coating antibody concentration value.

[0120] S1-2. Preparation of coated magnetic beads:

[0121] The magnetic beads were washed three times with 0.01 M sodium hydroxide, twice with purified water, and once with MES buffer. The beads were activated with EDC and NHS at room temperature for 32 minutes. Anti-GFAP mouse monoclonal antibody was added and coated at room temperature for 1.5 hours.

[0122] The beads were blocked with 1% BSA solution at room temperature for 50 minutes, and the magnetic beads were washed with magnetic bead buffer and stored to obtain coated magnetic beads.

[0123] S1-3. Preparation of magnetic bead buffer:

[0124] Weigh 800 g of purified water, 6.0 g of Tris HCl, 1.3 g of Tris Base, and 3.0 g of NaCl into a 2 L beaker. Use a pipette to draw 0.3 g of sodium azide, 1.5 g of Tween 20, and 20.0 mL of 0.5 M EDTA solution. Place the beaker on a magnetic stirrer and stir at 480 rpm for 22 min.

[0125] Stop stirring, weigh 12 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0126] After standing for 40 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.90 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 480 rpm for 12 minutes, and filtered through 0.22 μm.

[0127] S1-4. Preparation of magnetic beads reagent coated with anti-GFAP mouse monoclonal antibody:

[0128] Based on the anti-GFAP mouse monoclonal antibody concentration measured in step S1-1, calculate the required volume of magnetic bead buffer and the volume of anti-GFAP mouse monoclonal antibody-coated magnetic beads. Add the magnetic bead buffer to the EP tube, add the coated magnetic beads to the EP tube, and mix on a roller mixer at 70 rpm for 15 minutes.

[0129] The working concentration range of the obtained anti-GFAP mouse monoclonal antibody coated magnetic beads reagent is 1.2×10 7 beads / mL, recorded as magnetic bead reagent sample 2.

[0130] S2. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent

[0131] S2-1. Replacement buffer for biotin-labeled anti-GFAP mouse monoclonal antibody:

[0132] PBS buffer was added to the ultrafiltration tube, allowed to stand for 12 min, and centrifuged at 13,000 × g, 6 min, and 18°C.

[0133] Transfer the biotin-labeled anti-GFAP mouse monoclonal antibody to an ultrafiltration tube, add PBS buffer, and use a centrifuge for ultrafiltration. Centrifuge at 13,000 × g for 6 min and concentrate at 18°C. Repeat the cycle of adding PBS buffer 4 times.

[0134] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 800 × g, 3 min, and 18 °C.

[0135] The ultrafiltration tube was rinsed (PBS buffer was added to the inner tube) and then loaded into a centrifuge tube. The centrifugation conditions were 800 × g, 3 min, 18 °C.

[0136] The obtained antibodies were collected and the concentration of the biotin-labeled anti-GFAP mouse monoclonal antibody after the liquid exchange was determined using an ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (biotinylated) concentration value. The antibody concentration was diluted to 1 mg / mL using PBS buffer.

[0137] S2-2, anti-GFAP mouse monoclonal antibody labeled with biotin:

[0138] After removing 2 mg of EZ-Link NHS-PEG4-Biotin from a -20°C environment, equilibrate at room temperature for 35 minutes. Pipette 100 μL of dimethyl sulfoxide and add it to the biotin tube. Place the EP tube on a vortexer and mix for 32 seconds to obtain a biotin concentrate.

[0139] Add PBS buffer to the EP tube, pipette the biotin concentrate to prepare a 10 mM biotin dilution, and mix on a vortex for 12 seconds;

[0140] Add 5.5 μL of 10 mM biotin diluent to the EP tube containing 200 μg of antibody, mix on a vortex for 35 seconds, and place the centrifuge tube containing the reaction solution in a dark place at room temperature for 70 minutes;

[0141] Add PBS buffer to the ultrafiltration tube, let it stand for 12 minutes, centrifuge it, concentrate it at 13,000 × g for 5 minutes, and ultrafilter it at 18°C. Repeat this operation three times.

[0142] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 800 × g, 3 min, and 18 °C.

[0143] The ultrafiltration tube was then rinsed with PBS buffer and then loaded into a centrifuge tube. The centrifugation conditions were 800 × g, 3 min, 18°C ​​to collect the biotinylated antibody.

[0144] The concentration of the purified biotinylated antibody was determined using an ultra-micro-volume UV spectrophotometer.

[0145] S2-3. Preparation of biotinylated antibody buffer:

[0146] Weigh 850 g of purified water, 1.2 g of KH2PO4, 10.0 g of Na2HPO4·7H2O, 0.22 g of KCl, and 8.28 g of NaCl (the mass ratio of KCl to NaCl is 1:38) into a 2 L beaker.

[0147] 11 mL of 0.5 M EDTA solution, 1.5 g of Tween 20, and 0.3 g of sodium azide were pipetted into the beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 480 rpm for 18 min.

[0148] Stop stirring, weigh 18.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0149] After standing for 30 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.50 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 480 rpm for 12 minutes, and filtered through 0.22 μm.

[0150] S2-4. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent:

[0151] Based on the concentration of the purified biotinylated antibody measured in step S2-2, calculate the required volume of biotinylated antibody buffer and the volume of the purified biotinylated antibody. Add the required biotinylated antibody buffer to the EP tube, add the required biotinylated antibody to the EP tube, and place the tube on a roller mixer at 70 rpm to mix for 15 minutes. The resulting biotinylated anti-GFAP mouse monoclonal antibody reagent has a working concentration range of 0.3 μg / mL. This is recorded as biotinylated antibody reagent sample 2.

[0152] S3. Preparation of SBG reagent:

[0153] Weigh 800 g of purified water, 1.2 g / L KH2PO4, 8.29 g of NaCl, 0.21 g of KCl (the mass ratio of KCl to NaCl is 1:40), 10.0 g of Na2HPO4·7H2O, and 12.0 g of sucrose on a balance and add them to a 2 L beaker in that order;

[0154] Pipette 1.579 mL of 1 M MgCl2 solution (corresponding to 0.15 g of MgCl2), weigh 1.5 g of Tween 20 and 0.3 g of sodium azide, and add them to a 2 L beaker in sequence. Place the beaker on a magnetic stirrer and stir at 480 rpm for 32 min.

[0155] Stop stirring, weigh 25.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0156] After standing for 30 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.50 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 480 rpm for 32 minutes, and the mixture was filtered through a 0.22 μm filter membrane to obtain a SBG dilution solution;

[0157] Calculate the required volume based on the target working concentration of the SBG reagent and the labeled concentration of the streptavidin-β-galactosidase concentrate. Use a graduated cylinder and pipette to measure the required volume of SBG dilution and add it to a 200-mL beaker. Use a pipette to draw up the required volume of streptavidin-β-galactosidase concentrate and add it to the beaker. Place the beaker on a magnetic stirrer and stir at 480 rpm for 25 minutes to obtain an SBG reagent with a working concentration range of 80 pM, which is recorded as SBG reagent sample 2.

[0158] S4. Preparation of RGP reagent:

[0159] 900 g of purified water, 0.30 g of KH2PO4, 0.21 g of KCl, 8.79 g of NaCl (the mass ratio of KCl to NaCl is 1:42), 2.0 g of Na2HPO4·7H2O, 0.3 g of sodium azide, and 0.015 g of poloxamer were weighed on a balance and added to a 2 L beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 480 rpm for 70 min. The pH value was adjusted to 7.50 using 1 M NaOH solution. The volume was made up to 1000 g with purified water and stirred at 480 rpm for 18 min. The mixture was filtered through 0.22 μm to obtain an RGP dilution.

[0160] The drug bottle containing resorufin-β-D-galactoside solid, referred to as RGP drug bottle, was taken out from a -20°C environment and equilibrated at room temperature for 70 minutes. 1 mL of dimethyl sulfoxide was pipetted and then added to the equilibrated RGP drug bottle. The RGP drug bottle was placed on a vortex mixer for 8 seconds and then mixed on a roller mixer at 70 rpm for 20 minutes until the solid in the bottle was completely dissolved, thereby obtaining an RGP / DMSO solution.

[0161] Calculate the required volume based on the target working concentration of the RGP reagent and the content labeled on the RGP drug bottle; use a graduated cylinder and pipette to measure the required volume of RGP diluent and add it to a 1L brown glass bottle; use a pipette to draw up the required volume of RGP / DMSO solution and add it to the glass bottle. Place the glass bottle on a magnetic stirrer and stir at 480 rpm for 300 minutes to obtain an RGP reagent with a working concentration range of 40.0 μg / mL, which is recorded as RGP reagent sample 2.

[0162] S5. Preparation of dried plasma spot eluate:

[0163] Weigh 850 g of purified water, 12.0 g of HEPES, 15.0 g of NaCl, 2.0 g of EGTA, and 25.0 g of PEG6000 on a balance and add them sequentially to a 2 L beaker. Use a pipette to draw 11.0 mL of 0.5 M EDTA solution and 5 mL of 5 M NaOH solution in sequence. Weigh 12.0 g of Triton X-100 and 0.3 g of sodium azide and add them sequentially to the beaker. Place the beaker on a magnetic stirrer and stir at 480 rpm for 32 min.

[0164] Stop stirring, weigh 1.8 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0165] After standing for 30 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.50 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 480 rpm for 25 minutes. The mixture was filtered with a 0.22 μm filter membrane to obtain a dry plasma spot eluate, which was recorded as eluate sample 2.

[0166] S6, GFAP sample diluent:

[0167] 700 g of purified water, 1.2 g of KH2PO4, 10.0 g of Na2HPO4·7H2O, 0.21 g of KCl, and 8.29 g of NaCl (the mass ratio of KCl to NaCl is 1:40) were weighed on a balance and added sequentially to a 2 L beaker. 20.0 mL of 0.5 M EDTA solution was pipetted with a pipette, and 0.3 g of sodium azide, 2.0 g of Surfactant 10G, and 9.5 mg of TRU Block were weighed and added sequentially to the beaker. The beaker was placed on a magnetic stirrer and stirred at 480 rpm for 32 min.

[0168] Stop stirring, weigh 18.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0169] After standing for 30 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.50 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 480 rpm for 25 minutes. The mixture was filtered through a 0.22 μm filter membrane to obtain a GFAP sample dilution solution, which was recorded as dilution sample 2.

[0170] S7. Preparation of GFAP calibrator: same as in Example 1.

[0171] S8. Preparation of GFAP quality control product: same as in Example 1.

[0172] S9. Kit Assembly:

[0173] The magnetic bead reagent sample 2, biotinylated antibody reagent sample 2, SBG reagent sample 2, RGP reagent sample 2, eluent sample 2, diluent sample 2, calibrator sample and quality control sample prepared above were respectively combined with different filter papers to obtain different kit samples. The specific kit sample numbers and filter papers used are shown in Table 2.

[0174] Table 2: Reagents and filter paper combinations for different kits

[0175]

[0176] Example 3

[0177] In this example, a single-molecule fluorescence immunoassay kit for detecting GFAP protein in stem plasma plaques was prepared. The kit of this example includes a working concentration range of 0.8×10 7 The specific preparation steps are as follows: beads / mL anti-GFAP mouse monoclonal antibody-coated magnetic beads, biotinylated anti-GFAP mouse monoclonal antibody with a working concentration range of 0.5 μg / mL, SBG reagent with a working concentration range of 120 pM, RGP reagent with a working concentration range of 35 μg / mL, dried plasma spot eluent, GFAP sample diluent, GFAP calibrator, GFAP quality control product, and dried plasma spot filter paper.

[0178] S1. Prepare magnetic bead reagent by coating magnetic beads with anti-GFAP mouse monoclonal antibody:

[0179] S1-1, coating anti-GFAP mouse monoclonal antibody replacement buffer:

[0180] Add 50 mM MES buffer to the ultrafiltration tube, let it stand for 8 minutes, and centrifuge it at 15,000 × g for 4 minutes at 22°C.

[0181] Transfer the coated anti-GFAP mouse monoclonal antibody to an ultrafiltration tube, add 50 mM MES buffer, and use a centrifuge for ultrafiltration. Concentrate by centrifugation at 15,000 × g for 4 min at 22°C, and repeat the cycle of adding MES buffer three times.

[0182] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 800 × g, 3 min, 22 °C.

[0183] The ultrafiltration tube was then rinsed with 50 mM MES and loaded into a centrifuge tube. The centrifugation conditions were 800 × g, 3 min, and 22 °C.

[0184] The obtained antibodies were collected and the concentration of the anti-GFAP mouse monoclonal antibody (coating) after the liquid was changed was determined by ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (coating) concentration value, recorded as the coating antibody concentration value.

[0185] S1-2. Preparation of coated magnetic beads:

[0186] The magnetic beads were washed three times with 0.01 M sodium hydroxide, twice with purified water, and once with MES buffer. The beads were activated with EDC and NHS at room temperature for 28 min. Anti-GFAP mouse monoclonal antibody was added and coated at room temperature for 1.75 h.

[0187] The beads were blocked with 1% BSA solution at room temperature for 40 minutes, and the magnetic beads were washed with magnetic bead buffer and stored to obtain coated magnetic beads.

[0188] S1-3. Preparation of magnetic bead buffer:

[0189] Weigh 820 g of purified water, 5.0 g of Tris HCl, 2.0 g of Tris Base, and 2.5 g of NaCl into a 2 L beaker. Use a pipette to draw 0.8 g of Proclin 300, 0.5 g of Tween 20, and 19.0 mL of 0.5 M EDTA solution. Place the beaker on a magnetic stirrer and stir at 520 rpm for 18 min.

[0190] Stop stirring, weigh 8.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0191] After standing for 30 minutes without stirring, the mixture was stirred at 520 rpm for 28 minutes, the pH was adjusted to 7.70 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 520 rpm for 8 minutes, and filtered through 0.22 μm.

[0192] S1-4. Preparation of magnetic beads reagent coated with anti-GFAP mouse monoclonal antibody:

[0193] Based on the anti-GFAP mouse monoclonal antibody concentration measured in step S1-1, calculate the required volume of magnetic bead buffer and the volume of anti-GFAP mouse monoclonal antibody-coated magnetic beads. Add the magnetic bead buffer to the EP tube, add the coated magnetic beads to the EP tube, and mix on a roller mixer at 50 rpm for 25 minutes.

[0194] The working concentration range of the obtained anti-GFAP mouse monoclonal antibody coated magnetic beads reagent is 0.8×10 7 beads / mL, recorded as magnetic bead reagent sample 3.

[0195] S2. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent

[0196] S2-1. Replacement buffer for biotin-labeled anti-GFAP mouse monoclonal antibody:

[0197] PBS buffer was added to the ultrafiltration tube, allowed to stand for 8 min, and centrifuged at 15,000 × g for 4 min at 22°C.

[0198] Transfer the biotin-labeled anti-GFAP mouse monoclonal antibody to an ultrafiltration tube, add PBS buffer, and use a centrifuge for ultrafiltration. Concentrate by centrifugation at 15,000 × g for 4 min at 22°C, and repeat the cycle of adding PBS buffer three times.

[0199] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1200 × g, 1 min, 22 °C.

[0200] The ultrafiltration tube was rinsed (PBS buffer was added to the inner tube) and then loaded into a centrifuge tube. The centrifugation conditions were 1200 × g, 1 min, 22 °C.

[0201] The obtained antibodies were collected and the concentration of the biotin-labeled anti-GFAP mouse monoclonal antibody after the liquid exchange was determined using an ultra-micro UV spectrophotometer, which was the anti-GFAP mouse monoclonal antibody (biotinylated) concentration value. The antibody concentration was diluted to 1 mg / mL using PBS buffer.

[0202] S2-2, anti-GFAP mouse monoclonal antibody labeled with biotin:

[0203] After removing 2 mg of EZ-Link NHS-PEG4-Biotin from a -20°C environment, equilibrate at room temperature for 25 minutes. Pipette 100 μL of dimethyl sulfoxide and add it to the biotin tube. Place the EP tube on a vortexer and mix for 28 seconds to obtain a biotin concentrate.

[0204] Add PBS buffer to the EP tube, pipette the biotin concentrate to prepare a 10 mM biotin dilution, and mix on a vortex for 8 seconds;

[0205] Add 5.0 μL of 10 mM biotin diluent to the EP tube containing 200 μg of antibody, mix on a vortex for 25 seconds, and place the centrifuge tube containing the reaction solution in a dark place at room temperature for 50 minutes;

[0206] Add PBS buffer to the ultrafiltration tube, let it stand for 8 minutes, centrifuge it, concentrate it at 15,000 × g for 4 minutes, and ultrafilter it at 22°C. Repeat this operation 3 times.

[0207] After the last ultrafiltration, the inner tube was reversed and placed in another new centrifuge tube for recovery. The centrifugation conditions were 1200 × g, 1 min, 22 °C.

[0208] The ultrafiltration tube was then rinsed with PBS buffer and then loaded into a centrifuge tube. The centrifugation conditions were 1200 × g, 1 min, 22°C to collect the biotinylated antibody.

[0209] The concentration of the purified biotinylated antibody was determined using an ultra-micro-volume UV spectrophotometer.

[0210] S2-3. Preparation of biotinylated antibody buffer:

[0211] Weigh 750 g of purified water, 0.9 g of KH2PO4, 12.0 g of Na2HPO4·7H2O, 0.18 g of KCl, and 7.31 g of NaCl (the mass ratio of KCl to NaCl is 1:40) into a 2 L beaker.

[0212] 9 mL of 0.5 M EDTA solution, 0.5 g of Tween 20, and 0.8 g of Proclin 300 were pipetted into the beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 520 rpm for 12 min.

[0213] Stop stirring, weigh 20.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0214] After standing for 40 minutes without stirring, the mixture was stirred at 520 rpm for 28 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 520 rpm for 8 minutes, and filtered through 0.22 μm.

[0215] S2-4. Preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent:

[0216] Based on the concentration of the purified biotinylated antibody measured in step S2-2, calculate the required volume of biotinylated antibody buffer and the volume of the purified biotinylated antibody. Add the required biotinylated antibody buffer to the EP tube, add the required biotinylated antibody to the EP tube, and place the tube on a roller mixer at 50 rpm to mix for 25 minutes. The resulting biotinylated anti-GFAP mouse monoclonal antibody reagent has a working concentration range of 0.5 μg / mL. This is recorded as biotinylated antibody reagent sample 3.

[0217] S3. Preparation of SBG reagent:

[0218] Weigh 850 g of purified water, 1.2 g / L KH2PO4, 7.31 g of NaCl, 0.19 g of KCl (the mass ratio of KCl to NaCl is 1:38), 12.0 g of Na2HPO4·7H2O, and 8.0 g of sucrose on a balance and add them to a 2 L beaker in that order;

[0219] Pipette 0.526 mL of 1 M MgCl2 solution (corresponding to 0.05 g of MgCl2), weigh 0.5 g of Tween20 and 0.8 g of Proclin300, and add them to a 2 L beaker in sequence. Place the beaker on a magnetic stirrer and stir at 520 rpm for 28 min.

[0220] Stop stirring, weigh 35.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0221] After standing for 40 minutes without stirring, the mixture was stirred at 520 rpm for 28 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, the mixture was stirred at 520 rpm for 15 minutes, and the mixture was filtered through a 0.22 μm filter membrane to obtain a SBG dilution solution;

[0222] Calculate the required volume based on the target working concentration of the SBG reagent and the labeled concentration of the streptavidin-β-galactosidase concentrate. Use a graduated cylinder and pipette to measure the required volume of SBG diluent and add it to a 200-mL beaker. Use a pipette to draw up the required volume of streptavidin-β-galactosidase concentrate and add it to the beaker. Place the beaker on a magnetic stirrer and stir at 520 rpm for 15 minutes to obtain an SBG reagent with a working concentration range of 120 pM, which is recorded as SBG reagent sample 3.

[0223] S4. Preparation of RGP reagent:

[0224] 850 g of purified water, 0.15 g of KH2PO4, 0.20 g of KCl, 7.80 g of NaCl (the mass ratio of KCl to NaCl is 1:39), 2.5 g of Na2HPO4·7H2O, 0.8 g of Proclin300, and 0.005 g of poloxamer were weighed on a balance and added to a 2 L beaker in sequence. The beaker was placed on a magnetic stirrer and stirred at 520 rpm for 50 min. The pH value was adjusted to 7.40 using 1 M NaOH solution. The volume was made up to 1000 g with purified water and stirred at 520 rpm for 13 min. The solution was filtered through 0.22 μm to obtain an RGP dilution.

[0225] The drug bottle containing the solid resorufin-β-D-galactoside, referred to as the RGP drug bottle, was taken out from a -20°C environment and equilibrated at room temperature for 50 minutes. 1 mL of dimethyl sulfoxide was pipetted and then added to the equilibrated RGP drug bottle. The RGP drug bottle was placed on a vortex mixer for 12 seconds and then mixed on a roller mixer at 50 rpm for 40 minutes until the solid in the bottle was completely dissolved, thereby obtaining an RGP / DMSO solution.

[0226] Calculate the required volume based on the target working concentration of the RGP reagent and the content labeled on the RGP drug bottle; use a graduated cylinder and pipette to measure the required volume of RGP diluent and add it to a 1L brown glass bottle; use a pipette to draw up the required volume of RGP / DMSO solution and add it to the glass bottle, place the glass bottle on a magnetic stirrer, and stir at 520 rpm for 200 minutes to obtain an RGP reagent with a working concentration range of 35.0 μg / mL, recorded as RGP reagent sample 3.

[0227] S5. Preparation of dried plasma spot eluate:

[0228] Weigh 750 g of purified water, 11.0 g of HEPES, 20.0 g of NaCl, 1.5 g of EGTA, and 15.0 g of PEG6000 on a balance and add them sequentially to a 2 L beaker. Use a pipette to draw 9.0 mL of 0.5 M EDTA solution and 6.5 mL of 5 M NaOH solution, weigh 10.0 g of Triton X-100 and 0.6 g of Proclin 300, and add them sequentially to the beaker. Place the beaker on a magnetic stirrer and stir at 520 rpm for 28 min.

[0229] Stop stirring, weigh 1.2 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0230] After standing for 40 minutes without stirring, the mixture was stirred at 520 rpm for 28 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 520 rpm for 15 minutes. The mixture was filtered with a 0.22 μm filter membrane to obtain a dry plasma spot eluate, which was recorded as eluate sample 3.

[0231] S6, GFAP sample diluent:

[0232] 750 g of purified water, 0.9 g of KH2PO4, 12.0 g of Na2HPO4·7H2O, 0.19 g of KCl, and 7.31 g of NaCl (the mass ratio of KCl to NaCl is 1:38) were weighed on a balance and added sequentially to a 2 L beaker. 19.0 mL of 0.5 M EDTA solution was pipetted, and 0.8 g of Proclin 300, 1.8 g of surfactant Surfactant 10G, and 10.5 mg of blocking agent TRUBlock were weighed and added sequentially to the beaker. The beaker was placed on a magnetic stirrer and stirred at 520 rpm for 28 min.

[0233] Stop stirring, weigh 22.0 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0234] After standing for 40 minutes without stirring, the mixture was stirred at 520 rpm for 28 minutes, the pH was adjusted to 7.30 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 520 rpm for 15 minutes. The mixture was filtered through a 0.22 μm filter membrane to obtain a GFAP sample dilution solution, which was recorded as dilution sample 3.

[0235] S7. Preparation of GFAP calibrator: same as in Example 1.

[0236] S8. Preparation of GFAP quality control product: same as in Example 1.

[0237] S9. Kit Assembly:

[0238] The magnetic bead reagent sample 3, biotinylated antibody reagent sample 3, SBG reagent sample 3, RGP reagent sample 3, eluent sample 3, diluent sample 3, calibrator sample and quality control sample prepared above were respectively combined with different filter papers to obtain different kit samples. The specific kit sample numbers and filter papers used are shown in Table 3.

[0239] Table 3: Reagents and filter paper combinations for different kits

[0240]

[0241] Example 4

[0242] In this example, a single-molecule fluorescence immunoassay kit for detecting GFAP protein in stem plasma plaques was prepared. The kit of this example includes a working concentration range of 1.0×10 7The preparation steps of the S5 dried plasma spot eluate, GFAP sample diluent, GFAP calibrator, GFAP quality control product, and dried plasma spot filter paper were the same as those in Example 1, with the only differences being the preparation of the S5 dried plasma spot eluate and the assembly of the S9 reagent kit.

[0243] S5. During the preparation of the dried plasma spot eluate, the components of the dried plasma spot eluate of this embodiment further include hydroxypropyl-β-cyclodextrin, trehalose, and cocamidopropyl betaine. The specific process for preparing the dried plasma spot eluate of this embodiment S5 is as follows:

[0244] 800 g of purified water, 11.7 g of HEPES, 17.5 g of NaCl, 1.8 g of EGTA, 19.6 g of PEG6000, 17.5 g of hydroxypropyl-β-cyclodextrin, 7.5 g of trehalose, and 1.5 g of cocamidopropyl betaine were weighed on a balance and added sequentially to a 2 L beaker. 10.0 mL of 0.5 M EDTA solution and 6 mL of 5 M NaOH solution were pipetted sequentially. 11.0 g of Triton X-100 and 0.5 g of Proclin 300 were weighed and added sequentially to the beaker. The beaker was placed on a magnetic stirrer and stirred at 500 rpm for 30 min.

[0245] Stop stirring, weigh 1.5 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0246] After standing for 35 minutes without stirring, the mixture was stirred at 500 rpm for 30 minutes, the pH was adjusted to 7.40 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 500 rpm for 20 minutes. The mixture was filtered with a 0.22 μm filter membrane to obtain a dry plasma spot eluate, which was recorded as eluate sample 4.

[0247] S9. Kit Assembly:

[0248] The magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, eluent sample 4, diluent sample 1, calibrator sample and quality control sample prepared above were respectively combined with different filter papers to obtain different kit samples. The specific kit sample numbers and filter papers used are shown in Table 4.

[0249] Table 4: Reagents and filter paper combinations for different kits

[0250]

[0251] Example 5

[0252] In this example, a single-molecule fluorescence immunoassay kit for detecting GFAP protein in stem plasma plaques was prepared. The kit of this example includes a working concentration range of 1.2×10 7 The preparation steps of the S5 dried plasma spot eluate, the S9 dried plasma spot eluate, the S5 dried plasma spot eluate, and the S9 dried plasma spot filter paper were the same as those in Example 2, with the only differences being the preparation of the S5 dried plasma spot eluate and the assembly of the S9 reagent kit.

[0253] S5. During the preparation of the dried plasma spot eluate, the components of the dried plasma spot eluate of this embodiment further include hydroxypropyl-β-cyclodextrin, trehalose, and cocamidopropyl betaine. The specific process for preparing the dried plasma spot eluate of this embodiment S5 is as follows:

[0254] 850 g of purified water, 12.0 g of HEPES, 15.0 g of NaCl, 2.0 g of EGTA, 25.0 g of PEG6000, 20.0 g of hydroxypropyl-β-cyclodextrin, 5.0 g / L of trehalose, and 1.0 g / L of cocamidopropyl betaine were weighed on a balance and added sequentially to a 2 L beaker. 11.0 mL of 0.5 M EDTA solution and 5 mL of 5 M NaOH solution were pipetted sequentially. 12.0 g of Triton X-100 and 0.3 g of sodium azide were weighed and added sequentially to the beaker. The beaker was placed on a magnetic stirrer and stirred at 480 rpm for 32 min.

[0255] Stop stirring, weigh 1.8 g of BSA on a balance, and add it to the beaker, ensuring that the BSA is dispersed on the surface of the solution;

[0256] After standing for 30 minutes without stirring, the mixture was stirred at 480 rpm for 32 minutes, the pH was adjusted to 7.50 with 1 M NaOH solution, the volume was made up to 1000 g with purified water, and the mixture was stirred at 480 rpm for 25 minutes. The mixture was filtered with a 0.22 μm filter membrane to obtain a dry plasma spot eluate, which was recorded as eluate sample 5.

[0257] S9. Kit Assembly:

[0258] The above prepared magnetic bead reagent sample 2, biotinylated antibody reagent sample 2, SBG reagent sample 2, RGP reagent sample 2, eluent sample 5, diluent sample 2, calibrator sample and quality control sample were respectively combined with different filter papers to obtain different kit samples. The specific kit sample numbers and filter papers used are shown in Table 5.

[0259] Table 5: Reagent and filter paper combination table of different kits

[0260]

[0261] Example Six

[0262] In this embodiment, the preparation of the single molecule fluorescent immunoassay kit for detecting GFAP protein in dried blood plasma spots was carried out. The kit of this embodiment includes a working concentration range of 0.8 x 10 7 beads / mL anti-GFAP mouse monoclonal antibody coated magnetic beads reagent, a working concentration range of 0.5 μg / mL biotinylated anti-GFAP mouse monoclonal antibody reagent, a working concentration range of 120 pM SBG reagent, a working concentration range of 35 μg / mL RGP reagent, dried blood plasma spot eluent, GFAP sample diluent, GFAP calibrator, GFAP quality control and dried blood plasma spot filter paper. The specific preparation steps are the same as those of Example Three, except for the preparation of S5 dried blood plasma spot eluent and the combination of S9 kit.

[0263] During the preparation of S5, dried blood plasma spot eluent, the components of the dried blood plasma spot eluent of this embodiment also need to add hydroxypropyl-β-cyclodextrin, trehalose and cocamide propyl betaine. The specific process of preparing S5, dried blood plasma spot eluent of this embodiment is as follows:

[0264] Weigh 750 g of purified water, 11.0 g of HEPES, 20.0 g of NaCl, 1.5 g of EGTA, 15.0 g of PEG6000, 15.0 g of hydroxypropyl-β-cyclodextrin, 10.0 g / L of trehalose and 2.0 g / L of cocamide propyl betaine into a 2 L beaker in sequence. Use a pipette to take 9.0 mL of 0.5 M EDTA solution and 6.5 mL of 5 M NaOH solution in sequence. Weigh 10.0 g of Triton X-100 and 0.6 g of Proclin 300 and add them into the beaker in sequence. Place the beaker on a magnetic stirrer and stir at a speed of 520 rpm for 28 min.

[0265] Stop stirring, weigh 1.2 g of BSA and add it into the beaker, making sure that the BSA is dispersed on the surface of the solution.

[0266] After standing for 40 min without stirring, stirring at 520 rpm for 28 min, adjusting pH to 7.40 with 1 M NaOH solution, making up to 1000 g with purified water, stirring at 520 rpm for 15 min, and filtering with a 0.22 μm filter membrane, a dry blood plasma spot eluate was obtained, which was denoted as eluate sample 6.

[0267] S9, kit assembly:

[0268] The above-prepared magnetic bead reagent sample 3, biotinylated antibody reagent sample 3, SBG reagent sample 3, RGP reagent sample 3, eluate sample 6, diluent sample 3, calibrator sample, and quality control sample were respectively assembled with different filter papers to obtain different kit samples. The kit sample numbers and filter papers used are shown in Table 6.

[0269] Table 6: Assembly of reagents and filter papers of different kits

[0270]

[0271] Comparative Example 1

[0272] The implementation is the same as Example 1, except that in S5, 19.6 g of PEG 6000 is not added during the preparation of the dry blood plasma spot eluate, but an equal amount of PEG 4000 is added to prepare eluate control 1. According to Table 7, magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, diluent sample 1, calibrator sample, and quality control sample are assembled to obtain different kit controls.

[0273] Comparative Example 2

[0274] The implementation is the same as Example 1, except that in S5, 11.0 g of Triton X-100 is not added during the preparation of the dry blood plasma spot eluate, but an equal amount of Tween 20 is used to prepare eluate control 3. According to Table 7, magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, diluent sample 1, calibrator sample, and quality control sample are assembled to obtain kit controls.

[0275] Comparative Example 3

[0276] The implementation is the same as Example 4, except that in S5, 17.5 g of hydroxypropyl-β-cyclodextrin is not added during the preparation of the dry blood plasma spot eluate to prepare eluate control 4. According to Table 7, magnetic bead reagent sample 4, biotinylated antibody reagent sample 4, SBG reagent sample 4, RGP reagent sample 4, diluent sample 4, calibrator sample, and quality control sample are assembled to obtain kit controls.

[0277] Table 7: Reagents and filter paper combinations for different kits

[0278]

[0279]

[0280] Comparative Example 4

[0281] The implementation method is the same as that of Example 1, except that in the preparation process of S6 and GFAP sample diluent, instead of adding 1.9 g of Surfactant 10G, an equal mass of Triton X-100 is added to prepare diluent control substance 1, which is combined with magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, eluent sample 1, calibrator sample, and quality control sample according to Table 8 to obtain the kit control substance.

[0282] Comparative Example 5

[0283] The implementation method is the same as that of Example 1, except that during the preparation of S6 and GFAP sample diluent, 10.0 mg of the blocking agent TRU Block is not added, and the amount of BSA is increased from 19.0 g to 25.0 g to prepare a diluent control substance 2, which is combined with magnetic bead reagent sample 1, biotinylated antibody reagent sample 1, SBG reagent sample 1, RGP reagent sample 1, eluent sample 1, calibrator sample, and quality control sample according to Table 8 to obtain a kit control substance.

[0284] Comparative Example 6

[0285] The implementation method is the same as that of Example 1, except that in the preparation process of S6 and GFAP sample diluent, instead of adding 10.0 mg of the blocker TRU Block, an equal mass of the blocker HAMA is added to prepare the diluent control substance 3, which is combined with the magnetic bead reagent sample 1, the biotinylated antibody reagent sample 1, the SBG reagent sample 1, the RGP reagent sample 1, the eluent sample 1, the calibrator sample, and the quality control sample according to Table 8 to obtain the kit control substance.

[0286] Table 8: Reagents and filter paper combinations for different kits

[0287]

[0288] Analysis and testing

[0289] 1. Preliminary screening analysis test

[0290] Spiked samples: Take 1 mL of K2EDTA normal plasma sample and add different masses of GFAP calibrator to prepare low concentration sample of 1 pg / mL GFAP, medium concentration sample of 50 pg / mL GFAP, and high concentration sample of 800 pg / mL GFAP respectively;

[0291] Interference sample: Rheumatoid factor (RF) was added to the medium-concentration sample prepared above to prepare an RF interference sample with an RF concentration of 3000 IU / mL; triglyceride (TG) was added to the medium-concentration sample prepared above to prepare a TG interference sample with a TG concentration of 12 mmol / L.

[0292] 100 μL of the spiked sample and interference sample prepared above were respectively aspirated and spotted on the filter paper provided with the sample or reference substance in each kit. The filter paper was dried at room temperature of 25°C ± 1°C for 3 h and then stored in a sealed bag.

[0293] During the test, a 6 mm puncher was used to punch holes to obtain different dry plasma spot sample pieces with a diameter of 6 mm, which were then analyzed using a fully automatic single molecule fluorescence immunoassay analyzer UD-X.

[0294] Different dried plasma spot samples were added to the dried plasma spot eluate and mixed with oscillation at 25 ± 1°C for 2 h. The supernatant was collected and centrifuged at 14,000 × g for 10 min at 25°C. The supernatant was then aspirated for later use. Analysis was performed using the reagents corresponding to the samples or controls in the different kits: 75 μL of sample diluent, 25 μL of magnetic bead reagent, and 20 μL of biotin reagent. The reaction was allowed to proceed for 35 min. After washing, SBG reagent was added, and the reaction was continued for 5 min. After washing, 50 μL of RGP reagent was added. The AEB value was recorded. A standard curve was automatically fitted on the instrument, using the GFAP calibrator concentration as the horizontal axis and the AEB value as the vertical axis. The sample or control signal was automatically calculated to generate the concentration of the corresponding detection marker. Recovery and precision were calculated. The results are shown in Tables 9 and 10.

[0295] Table 9: Analysis results of spiked samples at different concentrations

[0296]

[0297]

[0298] Note: The CV values ​​in Table 9 are the standard deviations of the GFAP test results of different kit samples or controls obtained by combining the same reagent with different filter papers. They are used to examine the variation of the same reagent on different filter papers.

[0299] As can be seen from the results in Table 9, the kit samples prepared in Examples 1 to 6 of the present invention not only have a significantly higher recovery rate than the reference sample, but also have a higher applicability to different filter papers for the same reagent, as shown by the CV values ​​being all below 8.0%. However, some samples prepared in Example 1 showed a recovery rate below 85% in the test results for low-concentration samples (a recovery rate of 85% to 115% meets the pharmacopoeia requirements), which indicates that this group of kits does not meet the requirements and needs to reduce the degree of dependence on the reagents and the properties of the filter paper. The kit samples prepared in Examples 4 to 6, on the other hand, showed advantages such as a recovery rate closer to 100% and a higher applicability to filter paper in samples with various concentration gradients. This may be because the cyclodextrin component was added to the eluent of Examples 4 to 6, which reduced the adsorption loss of the filter paper by including hydrophobic proteins, and combined with PEG 6000 to provide steric hindrance to enhance the elution efficiency. Surfactant 10G in the diluent also showed advantages. The CV value of the kit control prepared in Comparative Example 4, in which Triton was used instead of the surfactant, soared to 19.7%. This may be because Triton caused the magnetic beads to aggregate, which shows the influence of the surfactant on the dispersion stability.

[0300] Table 10: Analysis results of different interfering samples

[0301]

[0302]

[0303] Note: The CV values ​​in Table 10 are the standard deviations of the GFAP test results of different kit samples or controls obtained using the same reagent and different filter paper combinations, and are used to examine the applicability of different reagents to filter paper.

[0304] As shown in Table 10, the test kit samples prepared by Examples 1 to 6 of the present invention showed higher anti-interference ability, and the influence of their anti-interference ability when paired with different types of filter paper groups was the lowest. However, some samples prepared by Example 1 also showed a recovery rate lower than 85% in the test results for high TG interference samples (the recovery rate was 85% to 115% to meet the pharmacopoeia requirements), which also shows that the reagents and the degree of dependence on the properties of the filter paper need to be reduced. The anti-interference advantage of the test kit samples prepared by Examples 4 to 6 is more obvious and more stable. This is also related to the optimization of the components of the eluent in Examples 4 to 6.

[0305] In summary, in the initial screening test of 48 kit samples and reference substances, it was found that the kit samples prepared in Examples 1 to 3 can meet the basic inspection requirements of the inspection process for samples of different concentrations and samples with different interference conditions, but the filter paper needs to be selected preferentially. Examples 4 to 6 optimized the eluent components, which not only improved the recovery rate of the kit, but also improved the adaptability to the type of filter paper.

[0306] 2. Verification of Kit Test Performance

[0307] Kit samples 1-1 and 4-1 to 4-4 were used to verify the performance of the kit, including sensitivity, detection limit, and linear range. The kit was used in the same manner as in "I. Initial Screening Test."

[0308] (1) Sensitivity and detection limit

[0309] The test was repeated 20 times using a zero-concentration calibrator (0 pg / mL GFAP). The concentration corresponding to the mean signal value + 2 × standard deviation was calculated to obtain the limit of detection (LoD). The results are shown in Table 11. Low-concentration samples close to the LoD value, namely, spiked samples of 0.5 pg / mL and 1.0 pg / mL, were selected and repeated 10 times. The CV value was required to be ≤20%. The limit of quantification (LoQ) was abbreviated. The results are shown in Tables 12 and 13.

[0310] Table 11: Detection limit verification results

[0311]

[0312] Table 12: Limit of Quantitation Verification Results (0.5 pg / mL Spiked Sample)

[0313]

[0314] Table 13: Limit of Quantitation Verification Results (1.0 pg / mL Spiked Sample)

[0315]

[0316] As shown in Tables 11 to 13, the present invention kit samples 1-1 and 4-1 to 4-4 had CVs ≤ 5.3% and recoveries of 97.4% to 100.4% at a concentration of 0.5 pg / mL, meeting the LoQ requirements (CV ≤ 20%, recovery 85% to 115%). This indicates that the limits of quantitation for the present invention kit samples all reached 0.5 pg / mL. Furthermore, at a concentration of 1.0 pg / mL, the CVs for kit samples 1-1 and 4-1 to 4-4 were ≤ 3.5%, indicating that the precision of the optimized formulations of Examples 4 to 6 (CV 1.5% to 2.2%) approached the instrument detection limit.

[0317] (2) Linear

[0318] The high concentration sample (800 pg / mL) was diluted in proportion (1:2, 1:4, 1:8, 1:16, 1:32, 1:64), and the measured concentration was linearly regressed with the theoretical concentration. The R 2 Not less than 0.98, see the results Figures 1 to 5 (Corresponding to kit sample 1-1 and kit samples 4-1 to 4-4, respectively.) The horizontal axis represents the theoretical concentration of the marker (pg / mL), and the vertical axis represents the measured concentration of the marker (pg / mL).

[0319] Depend on Figures 1 to 5 It can be seen that the R corresponding to the kit sample 1-1 and the kit samples 4-1 to 4-4 of the present invention 2 The values ​​are all higher than 0.98, which meets the linear requirements.

[0320] 3. Verification of kit stability

[0321] Kit sample 1-1 and kit samples 4-1 to 4-4 were selected to verify the stability of the kit. That is, the kit was stored at 4°C, and the medium concentration quality control product (50 pg / mL) was tested on days 0, 3, 7, and 9 after opening. The signal change compared with day 0 should be ≤15%. The results are shown in Table 14.

[0322] Table 14: Kit stability verification results

[0323]

[0324] As can be seen from the results in Table 14, the signal attenuation of the test kit sample 1-1 using the basic eluent formula was 12% on the 9th day, which is close to the critical value of the acceptable range, while the signal attenuation of the test kit samples 4-1 to 4-4 using the improved eluent formula was ≤2.5% on the 9th day, which fully met the requirements. It can be seen that the improved formula can reduce the degradation of reagent components.

[0325] 4. Verification of the stability of dried plasma spot samples at room temperature

[0326] Three plasma samples were prepared into dried plasma spot samples using the filter papers corresponding to kit sample 1-1 and kit samples 4-1 to 4-4, respectively. The dried plasma spot samples were placed at room temperature for 6 months and tested on day 0, 1 month, 2 months, and 6 months, respectively. The test results are recorded in Tables 15 to 17.

[0327] Blood was collected by venous sampling, and the anticoagulant type was K2EDTA. The storage conditions before the experiment in this example were the same, that is, the sample was frozen for less than 30 days and repeated freezing and thawing was avoided.

[0328] Table 15: Test results of different kits for plasma sample 1

[0329]

[0330] Table 16: Test results of different kits for plasma sample 2

[0331]

[0332] Table 17: Test results of different kits for plasma sample 2

[0333]

[0334] As shown in Tables 15 to 17, the detection concentration of samples 4-1 to 4-4 of the kit with the improved eluent formula decreased significantly after 6 months of storage at room temperature in the dried plasma spot samples compared to sample 1-1 of the kit with the basic formula. This may be because the improved eluent components can reduce filter paper adsorption and protein degradation. For the unified reagent combination, Whatman 903 filter paper has the best stability, while Ahlstrom 226 filter paper is slightly worse. This may be because the hydrophobic filter paper requires a higher concentration of cyclodextrin to compensate.

[0335] The embodiments described above are merely descriptions of preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by persons skilled in the art should fall within the scope of protection defined by the claims of the present invention.

Claims

1. A single molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma plaques, characterized in that: The kit includes an anti-GFAP mouse monoclonal antibody-coated magnetic bead reagent, a biotinylated anti-GFAP mouse monoclonal antibody reagent, a streptavidin-β-galactosidase reagent, a resorufin β-D-galactoside reagent, a dry plasma spot eluent, a GFAP sample diluent, a GFAP calibrator, a GFAP quality control product, and a dry plasma spot filter paper; the dry plasma spot eluent contains 15g / L to 25g / L PEG 6000, 15g / L to 20g / L NaCl, 11g / L to 12g / L HEPES, and 10g / L to 12g / L Triton. X-100, 4.5mmol / L~5.5mmol / L EDTA, 1.5g / L~2.0g / L EGTA and 1.2g / L~1.8g / L BSA, the matrix is ​​water, and the pH value is adjusted to 7.3~7.5 with NaOH; streptavidin-β-galactosidase reagent is abbreviated as SBG reagent, and resorufin β-D-galactoside reagent is abbreviated as RGP reagent.

2. The single molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots according to claim 1, characterized in that: The dried plasma spot eluate further comprises 15 g / L to 20 g / L of hydroxypropyl-β-cyclodextrin, 5 g / L to 10 g / L of trehalose and 1.0 g / L to 2.0 g / L of cocamidopropyl betaine.

3. The single molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots according to claim 1, characterized in that: The dried plasma spot eluate further includes 0.2 g / L to 0.6 g / L of a preservative, which is Proclin 300 or sodium azide.

4. The single molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots according to claim 1, characterized in that: The GFAP calibrator contains 8 concentration points: 1000 pg / mL, 333.3 pg / mL, 111.1 pg / mL, 37.04 pg / mL, 12.35 pg / mL, 4.12 pg / mL, 1.37 pg / mL and 0 pg / mL; the working concentration range of the magnetic bead reagent coated with anti-GFAP mouse monoclonal antibody is 0.8×10 7 beads / mL~1.2×10 7 beads / mL; the working concentration range of the biotinylated anti-GFAP mouse monoclonal antibody reagent is 0.3 μg / mL to 0.5 μg / mL; the working concentration range of the SBG reagent is 80 pM to 120 pM; the working concentration range of the RGP reagent is 35 μg / mL to 40 μg / mL; and the dried plasma spot filter paper includes any one of Whatman 903 filter paper, Hahnemühle 2992 filter paper, PerkinElmer 226 filter paper, or Ahlstrom 226 filter paper.

5. The single molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots according to claim 1, characterized in that: The GFAP sample diluent contains: 18g / L to 22g / L BSA, 7.5g / L to 8.5g / L chloride, 0.9g / L to 1.2g / L KH2PO4, 10g / L to 12g / L Na2HPO4·7H2O, 9.5mmol / L to 10.0mmol / L EDTA, 1.8g / L to 2.2g / L surfactant and 9.5mg / L to 10.5mg / L blocking agent. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH; the chloride is KCl and NaCl in a mass ratio of 1:38 to 40; the surfactant is Surfactant 10G; and the blocking agent is TRU Block blocking agent.

6. A method for preparing a single-molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots, which is used to prepare the single-molecule fluorescence immunoassay kit for detecting GFAP protein in dry plasma spots according to any one of claims 1 to 5, characterized in that: The preparation method includes: S1, preparing a magnetic bead reagent by coating magnetic beads with anti-GFAP mouse monoclonal antibody, S2, preparing a biotinylated anti-GFAP mouse monoclonal antibody reagent, S3, preparing an SBG reagent, S4, preparing an RGP reagent, S5, preparing a dried plasma spot eluate, S6, preparing a GFAP sample diluent, S7, preparing a GFAP calibrator, and S8, preparing a GFAP quality control product.

7. The preparation method according to claim 6, characterized in that Step S1 includes S1-1, replacement of buffer by coating anti-GFAP mouse monoclonal antibody, S1-2, preparation of coated magnetic beads, S1-3, preparation of magnetic bead buffer, and S1-4, preparation of magnetic bead reagent product coated with anti-GFAP mouse monoclonal antibody; Step S1-1 is to concentrate and replace the solution through an ultrafiltration tube. Specifically, the coated anti-GFAP mouse monoclonal antibody solution is added to the ultrafiltration tube, centrifuged at 13,000×g to 15,000×g for 4 to 6 minutes, and then the solution is repeatedly added with MES buffer for 3 to 4 times to collect the antibody. The concentration of the coated anti-GFAP mouse monoclonal antibody after the solution replacement is measured using an ultramicro UV spectrophotometer and recorded as the coated antibody concentration value; Step S1-2 is to wash the magnetic beads with 0.01M sodium hydroxide, purified water, and MES buffer in sequence, activate the magnetic beads with EDC and NHS at room temperature, add the coated anti-GFAP mouse monoclonal antibody after the replacement solution, and coat the magnetic beads at room temperature for 1.5 hours to 2 hours, and add BSA to block the magnetic beads to obtain coated magnetic beads; In step S1-3, a magnetic bead storage buffer solution is prepared. The prepared magnetic bead storage solution contains 8 g / L to 12 g / L BSA, 5 g / L to 6 g / L Tris HCl, 1.3 g / L to 2.0 g / L Tris Base, 2.5 g / L to 3.0 g / L NaCl, 0.5 g / L to 1.5 g / L Tween 20, 9.5 mmol / L to 10.0 mmol / L EDTA, and 0.3 g / L to 0.8 g / L preservative. The matrix is ​​water, and the pH value is adjusted to 7.7 to 7.9 with NaOH. Step S1-4 is to calculate the required volume of magnetic bead buffer and the volume of anti-GFAP mouse monoclonal antibody-coated magnetic beads based on the anti-GFAP mouse monoclonal antibody concentration measured in step S1-1, so that the working concentration range of the obtained anti-GFAP mouse monoclonal antibody-coated magnetic bead reagent is 0.8×10 7 beads / mL~1.2×10 7 beads / mL.

8. The preparation method according to claim 6, characterized in that Step S2 includes S2-1, replacement buffer of anti-GFAP mouse monoclonal antibody labeled with biotin, S2-2, labeling anti-GFAP mouse monoclonal antibody with biotin, S2-3, preparation of biotinylated antibody buffer, and S2-4, preparation of biotinylated anti-GFAP mouse monoclonal antibody reagent product; Step S2-1 involves concentrating and replacing the solution using an ultrafiltration tube. Specifically, a biotin-labeled anti-GFAP mouse monoclonal antibody solution is added to an ultrafiltration tube, concentrated by centrifugation at 13,000 × g to 15,000 × g for 4 to 6 minutes, and the solution is repeatedly added with PBS buffer for 3 to 4 times to collect the antibody. The concentration of the biotin-labeled anti-GFAP mouse monoclonal antibody after the replacement solution is determined using an ultramicro-UV spectrophotometer. Step S2-2 comprises dissolving NHS-PEG4-Biotin in dimethyl sulfoxide to prepare a biotin concentrate, which is then diluted with PBS buffer to a 10 mM biotin working solution; adding the 10 mM biotin working solution to the replaced biotin-labeled anti-GFAP mouse monoclonal antibody solution for labeling, vortex mixing, and reacting at room temperature in the dark for 50 to 70 minutes to obtain a crude biotinylated antibody product, wherein the molar ratio of the biotin-labeled anti-GFAP mouse monoclonal antibody to biotin is 1:10; purifying the product by ultrafiltration to remove free biotin to obtain a purified biotinylated antibody, and measuring the concentration of the purified biotinylated antibody by an ultramicro-UV spectrophotometer; In step S2-3, a biotinylated antibody buffer is prepared, which comprises 18 g / L to 22 g / L BSA, 7.5 g / L to 8.5 g / L chloride, 0.9 g / L to 1.2 g / L KH2PO4, 10 g / L to 12 g / L Na2HPO4·7H2O, 4.5 mmol / L to 5.5 mmol / L EDTA, 0.5 g / L to 1.5 g / L Tween20, and 0.3 g / L to 0.8 g / L preservative. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH. The chloride is KCl and NaCl in a mass ratio of 1:38 to 40. Step S2-4 is to calculate the required volume of biotinylated antibody buffer and the volume of purified biotinylated antibody based on the concentration of the purified biotinylated antibody measured in step S2-2, so that the working concentration range of the obtained biotinylated anti-GFAP mouse monoclonal antibody reagent is 0.3 μg / mL to 0.5 μg / mL.

9. The preparation method according to claim 6, characterized in that The S3 step is to dilute the streptavidin-β-galactosidase concentrate to a working concentration range of 80 pM to 120 pM using SBG diluent, wherein the SBG diluent contains 25 g / L to 35 g / L BSA, 8 g / L to 12 g / L sucrose, 7.5 g / L to 8.5 g / L chloride salt, 0.9 g / L to 1.2 g / L KH2PO4, 10 g / L to 12 g / L Na2HPO4·7H2O, 0.5 g / L to 1.5 g / L Tween 20, 0.05 g / L to 0.15 g / L MgCl2, and 0.3 g / L to 0.8 g / L preservative. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH. The chloride salt is KCl and NaCl in a mass ratio of 1:38 to 40.

10. The preparation method according to claim 6, characterized in that The S4 step is to dissolve resorufin-β-D-galactoside in dimethyl sulfoxide, and then dilute it with RGP diluent to a working concentration range of 35 μg / mL to 40 μg / mL, wherein the RGP diluent contains 8.0 g / L to 9.0 g / L of chloride salt, 0.15 g / L to 0.30 g / L of KH2PO4, 2.0 g / L to 2.5 g / L of Na2HPO4·7H2O, 0.005 g / L to 0.015 g / L of poloxamer, and 0.3 g / L to 0.8 g / L of preservative. The matrix is ​​water, and the pH value is adjusted to 7.3 to 7.5 with NaOH; the chloride salt is KCl and NaCl with a mass ratio of 1:39 to 42.

Citation Information

Patent Citations

  • Kit for quantitatively detecting GFAP and application of kit

    CN112485445A

  • GFAP quantitative detection kit and application

    CN117074701A